Corvus Pharmaceuticals/$CRVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Ticker
$CRVS
Sector
Primary listing
Employees
37
Headquarters
Website
CRVS Metrics
BasicAdvanced
$1.1B
-
-$0.53
0.85
-
Price and volume
Market cap
$1.1B
Beta
0.85
52-week high
$26.95
52-week low
$2.54
Average daily volume
1.4M
Financial strength
Current ratio
6.206
Quick ratio
6.09
Long term debt to equity
0.872
Total debt to equity
1.531
Profitability
EBITDA (TTM)
-42.866
Management effectiveness
Return on assets (TTM)
-38.36%
Return on equity (TTM)
-32.60%
Valuation
Price to book
16.05
Price to tangible book (TTM)
16.05
Price to free cash flow (TTM)
-31.494
Free cash flow yield (TTM)
-3.18%
Free cash flow per share (TTM)
-0.418
Growth
Earnings per share change (TTM)
-47.92%
3-year earnings per share growth (CAGR)
-15.68%
10-year earnings per share growth (CAGR)
-39.71%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
CRVS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $1.1B as of March 25, 2026.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of March 25, 2026.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of March 25, 2026.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.